Neurocrine Biosciences, Inc. (NBIX)
Company Info
US64125C1099
64125C109
May 23, 1996
Highlights
$11.79B
$2.95
40.38
0.27
$2.41B
$2.37B
$539.80M
$84.23 - $157.98
$159.40
6.05%
2.53
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Neurocrine Biosciences, Inc. (NBIX) returned -11.96% year-to-date (YTD) and -14.47% over the past 12 months. Over the past 10 years, NBIX had an annualized return of 11.01%, slightly ahead of the S&P 500 benchmark at 10.68%.
NBIX
-11.96%
16.43%
-4.35%
-14.47%
12.41%
-0.75%
11.01%
^GSPC (Benchmark)
-1.34%
7.94%
-2.79%
10.16%
13.76%
14.45%
10.68%
Monthly Returns
The table below presents the monthly returns of NBIX, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 11.22% | -21.80% | -6.84% | -2.63% | 11.60% | -11.96% | |||||||
| 2024 | 6.08% | -6.70% | 5.77% | -0.28% | -1.55% | 1.67% | 2.83% | -10.25% | -9.32% | 4.38% | 5.39% | 7.69% | 3.60% |
| 2023 | -7.12% | -7.06% | -1.82% | -0.18% | -11.39% | 5.33% | 8.05% | 6.87% | 3.32% | -1.39% | 5.09% | 13.01% | 10.31% |
| 2022 | -7.22% | 13.73% | 4.32% | -3.97% | 3.84% | 4.27% | -3.44% | 11.15% | 1.51% | 8.39% | 10.37% | -6.00% | 40.24% |
| 2021 | 14.50% | -0.22% | -11.20% | -2.84% | 1.83% | 1.14% | -4.22% | 2.13% | 0.75% | 9.91% | -21.02% | 2.31% | -11.14% |
| 2020 | -6.89% | -5.38% | -8.61% | 13.39% | 27.12% | -2.21% | -1.34% | -3.27% | -17.40% | 2.61% | -3.78% | 0.96% | -10.83% |
| 2019 | 23.54% | -12.43% | 14.05% | -18.00% | 17.36% | -0.41% | 14.17% | 3.14% | -9.36% | 10.41% | 17.21% | -7.82% | 50.53% |
| 2018 | 10.16% | -1.22% | -1.78% | -2.23% | 18.72% | 2.06% | 2.29% | 22.35% | 0.00% | -12.85% | -17.62% | -19.10% | -7.96% |
| 2017 | 10.88% | 2.91% | -1.95% | 23.33% | -18.60% | 5.82% | 4.41% | 17.84% | 8.27% | 1.35% | 15.75% | 7.93% | 100.49% |
| 2016 | -24.78% | -13.56% | 7.53% | 15.25% | 8.93% | -8.46% | 10.52% | -3.52% | 4.50% | -13.57% | 6.12% | -16.68% | -31.59% |
| 2015 | 50.67% | 16.01% | 1.69% | -14.15% | 28.66% | 8.89% | 4.94% | -7.46% | -14.21% | 23.37% | 10.76% | 4.05% | 153.22% |
| 2014 | 82.98% | 3.16% | -8.68% | -12.92% | -0.93% | 6.80% | -8.46% | 20.10% | -3.92% | 18.19% | 7.61% | 12.09% | 139.19% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of NBIX is 32, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Neurocrine Biosciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Neurocrine Biosciences, Inc. was 97.21%, occurring on Nov 12, 2009. Recovery took 2007 trading sessions.
The current Neurocrine Biosciences, Inc. drawdown is 21.60%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.21% | Mar 16, 2006 | 924 | Nov 12, 2009 | 2007 | Nov 2, 2017 | 2931 |
| -70.28% | Feb 27, 1997 | 605 | Jul 22, 1999 | 86 | Nov 22, 1999 | 691 |
| -66.16% | Mar 6, 2000 | 257 | Mar 12, 2001 | 173 | Nov 20, 2001 | 430 |
| -54.12% | Dec 26, 2001 | 135 | Jul 10, 2002 | 228 | Jun 5, 2003 | 363 |
| -50.71% | Apr 28, 2004 | 255 | May 2, 2005 | 207 | Feb 27, 2006 | 462 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Neurocrine Biosciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Neurocrine Biosciences, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -36.0%.
Valuation
The Valuation section provides an overview of how Neurocrine Biosciences, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for NBIX, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, NBIX has a P/E ratio of 40.4. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for NBIX compared to other companies in the Drug Manufacturers - Specialty & Generic industry. NBIX currently has a PEG ratio of 0.3. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NBIX relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, NBIX has a P/S ratio of 4.9. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for NBIX in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, NBIX has a P/B value of 4.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |